VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis.

Crit Care · 2009 · PMC2784364 · PMID 19740426

Europe PMC DOI

hedged sentence

0.1900

closest p · 3.8× alpha

0.1900

boldest claim

The sentences

did not quite reach statistical significanceP = 0.19not close (p > 0.1)

When initiation of treatment was delayed further, eight hours post-CLP, VX-166 still improved survival from 40% to 66%; this result did not quite reach statistical significance ( P = 0.19, Figure 4c ).

also in 679 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.